WEST CHESTER, Pa. (BUSINESS WIRE) Papyrus Therapeutics Inc. is delighted to announce that two new members have joined our Board of Directors, Marc Beer as chairman and Professor James Lorens PhD as an independent director.Marc brings more then 30 years of therapeutic development and commercialization experience in.
Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality
- The parties will explore the feasibility and effect of combining their respective oncolytic virus and receptor tyrosine kinase (RTK) inhibitor technologies
- Targovax retains the right to develop and commercialize novel drug candidates emerging from the pre-clinical collaboration
News provided by
Share this article
OSLO, Norway, Feb. 10, 2021 /PRNewswire/
Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that it has entered into a research collaboration agreement with Papyrus Therapeutics to assess the potential of combining their respective proprietary technology platforms to develop a first-in-class oncolytic virus concept with RTK inhibitor functionality.